GALVUS NOVARTIS PDFGALVUS NOVARTIS PDF

Novartis’ Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV inhibitors (DPP-IV) inhibitors or ‘incretin . Galvus Approval Status. FDA Approved: No Brand name: Galvus Generic name: vildagliptin. Previous Name: LAF Company: Novartis Pharmaceuticals. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral.

Author: Yozshushicage Nejinn
Country: Comoros
Language: English (Spanish)
Genre: Education
Published (Last): 27 June 2009
Pages: 52
PDF File Size: 17.87 Mb
ePub File Size: 10.78 Mb
ISBN: 470-9-70657-394-5
Downloads: 86923
Price: Free* [*Free Regsitration Required]
Uploader: Moogusho

Two patients reported severe hypoglycaemic events in the vildagliptin group, and 6 patients in the placebo group. Cibenzoline The risk ggalvus severity of hypoglycemia can be increased when Cibenzoline is combined with Vildagliptin.

Hydrochlorothiazide The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydrochlorothiazide. Sulfaguanidine The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfaguanidine. It must also not be used in patients with alcohol intoxication excessive alcohol consumption or alcoholism, or during breast-feeding.

Oral anti-diabetic drugsinsulins and insulin analogsand other drugs used in novartiis A The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Vildagliptin.

Insulin Human Vildagliptin may increase the hypoglycemic activities of Insulin Human. The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Benfluorex.

Galvus 50 mg Tablets – Summary of Product Characteristics (SmPC) – (eMC)

European Medicines Agency investigates findings on pancreatic risks with GLPbased therapies for type-2 diabetes. Bempedoic acid The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Bempedoic acid.

  576 KBYTE MAGAZINE PDF

Enalaprilat The ggalvus or severity of angioedema can be increased when Vildagliptin is combined with Enalaprilat.

Mefruside The therapeutic efficacy of Vildagliptin bovartis be increased when used in combination with Mefruside. Pipotiazine The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pipotiazine. The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Vildagliptin.

Vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing CHF. The risk or severity of hypoglycemia can be increased when AICA ribonucleotide is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Metolazone. Bismuth Subsalicylate Bismuth Subsalicylate may increase the hypoglycemic activities of Vildagliptin. Bencyclane The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Vildagliptin.

Vildagliptin – DrugBank

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Darunavir. Piperazine The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Piperazine.

Insulin Beef The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Insulin Beef. Prednisolone The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisolone.

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quetiapine.

The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Ethoxzolamide. novaryis

  AUTOPSIA PSICOLOGICA TERESITA PDF

Vildagliptin launched by Novartis for dual therapy in type 2 diabetes

Pirlindole Pirlindole may increase the hypoglycemic activities of Vildagliptin. Sulfadimethoxine The therapeutic efficacy of Vildagliptin can be increased when used in galvys with Sulfadimethoxine. Amineptine Amineptine may decrease the hypoglycemic activities of Vildagliptin. The risk or severity of hypoglycemia can be increased when Ritanserin is combined with Vildagliptin.

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with St. Sulfaethoxypyridazine The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfaethoxypyridazine.

The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Vildagliptin. The risk or severity of hypoglycemia glavus be increased when Buformin is combined with Vildagliptin.

Therefore Galvus should be used with caution in these patients see also sections 4. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Fluticasone furoate. Grepafloxacin The therapeutic efficacy of Vildagliptin can be increased when used in nkvartis with Grepafloxacin. Rasagiline Rasagiline may increase the hypoglycemic activities of Vildagliptin.

Englitazone The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Englitazone.